Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.370
-0.020 (-0.84%)
Jun 5, 2025, 4:00 PM - Market closed
Vistagen Therapeutics Employees
As of March 31, 2024, Vistagen Therapeutics had 40 total employees, including 39 full-time and 1 part-time employees. The number of employees increased by 6 or 17.65% compared to the previous year.
Employees
40
Change (1Y)
6
Growth (1Y)
17.65%
Revenue / Employee
$17,450
Profits / Employee
-$1,182,600
Market Cap
68.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VTGN News
- 3 days ago - Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Business Wire
- 8 days ago - Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - Business Wire
- 13 days ago - Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - Business Wire
- 7 weeks ago - Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Business Wire
- 2 months ago - Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Business Wire
- 3 months ago - Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire
- 3 months ago - Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - Business Wire
- 3 months ago - Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication - Seeking Alpha